Pam Taak is an intellectual property lawyer based in London. She advises clients on the full range of intellectual property rights including patents, design rights, copyright, database rights, trade marks, brands and trade secrets. Pam has a wide range of experience of handling cross-border patent, IP and licensing disputes across a number of industry sectors, including the life sciences and healthcare, mechanical and software, and telecommunications fields.
Much of Pam’s work has focussed on acting for clients in the pharmaceutical and biotechnology sectors – for example, at her previous firm, she acted in several high profile cases such as MedImmune v Novartis, where she acted for Novartis in successfully defending the patent litigation launched by MedImmune in respect of Novartis's sight-saving drug Lucentis, and also Warner-Lambert v Teva, where she acted for Pfizer in preventing the “at-risk” launch by generic companies (such as Teva) of Pfizer's blockbuster drug, Lipitor. She has also provided product life-cycle management advice to major pharmaceutical clients and their patent positioning strategies in Europe.
Pam is a qualified solicitor advocate, having obtained Higher Rights of Audience (UK High Court) in 2014. Pam is also an associate member of the Chartered Institute of Patent Attorneys. She has obtained a first-class degree in Natural Sciences from the University of Cambridge, as well as a commendation award in the IP Law and Practice Diploma from the University of Oxford.
The European life sciences team at Norton Rose Fulbright invite you to attend their annual life sciences conference..
November 9, 2017
The European Commission’s Directorate General for Internal Market, Industry, Entrepreneurship and SMEs plans to contract a legal study on the EU system of Supplement.
February 03, 2016
Shanks v Unilever: Arnold upholds UKIPO decision not to award employee inventor compensation under section 40 Patents Act 1977..
May 28, 2014